Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Boris J. N. Winterhoff, Stefan Kommoss, Ann L. Oberg, Chen Wang, Shaun M. Riska, Gottfried E. Konecny, Jian-Bing Fan, Viji Shridhar, Ellen L. Goode, Friedrich Kommoss, Andreas Du Bois, Felix Hilpert, Jeremy Chien, Andrew Christopher Embleton, Mahesh Parmar, Richard S. Kaplan, Timothy Perren, Lynn C. Hartmann, Jacobus Pfisterer, Sean Christopher Dowdy
Institutions: Mayo Clinic, University of Tübingen, University of California, Los Angeles, Illumina (United States), Kliniken Essen-Mitte, Christian-Albrechts-Universität zu Kiel, University of Kansas Medical Center, MRC Clinical Trials Unit at UCL, University College London, St James's University Hospital
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2311259501